Disclosure Decoder
Disclosure Decoder #011: Samsung Biologics' smaller rights offering leaves KRW 336bn of spending to its own funds
Samsung Biologics' first-round price of KRW 1.174mn (~$862) cuts indicated proceeds to KRW 2,665bn (~$1,956M). Under its stated priority order, the whole raise now goes to the securities acquisition and the KRW 295bn (~$216M) facility line drops out.